BioCentury
ARTICLE | Financial News

Impact raises $30M series C

August 2, 2018 7:50 PM UTC

Impact Therapeutics Inc. (Nanjing, China) raised $30 million in an untranched series C round led by new investor Decheng Capital. Existing investor Lilly Asia Ventures also participated.

Impact is developing IMP4297, a PARP-1 inhibitor that is in Phase I testing to treat advanced solid tumors. SVP and CTO Sui Xiong Cai told BioCentury the company plans to start Phase Ib/II testing of the candidate by year-end for an undisclosed cancer indication...